Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary - Top-Institutions - MDSpire

Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary

  • By

  • Charlotte A. Leseman

  • Alessandro M. Bonomi

  • Job Schuitema

  • Stefano Granieri

  • Margaret Sällberg Chen

  • Ajay V. Maker

  • Zeeshan Ateeb

  • Laura D. Wood

  • Rogier P. Voermans

  • Giovanni Marchegiani

  • Marco Del Chiaro

  • Johannes C. F. Ket

  • Anne Marie Lennon

  • Marc G. Besselink

  • Global Evidence-Based Guidelines for the Management of Pancreatic Cystic Neoplasms Group

  • June 26, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Amsterdam UMC
    Amsterdam UMC

    Amsterdam, North Holland

    Key Differentiators

    • Oncology

  • #2

    Hirosaki University Graduate School of Medicine
    Hirosaki University Graduate School of Medicine

    Hirosaki, Aomori

    Key Differentiators

    • Oncology

  • #3

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Oncology

  • #5

    S. Orsola-Malpighi Hospital
    S. Orsola-Malpighi Hospital

    Bologna, Emilia-Romagna

    Key Differentiators

    • Oncology

Original Source(s)

Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary

  • by Charlotte A. Leseman, Alessandro M. Bonomi, Job Schuitema, Stefano Granieri, Margaret Sällberg Chen, Ajay V. Maker, Zeeshan Ateeb, Laura D. Wood, Rogier P. Voermans, Giovanni Marchegiani, Marco Del Chiaro, Johannes C. F. Ket, Anne Marie Lennon, Marc G. Besselink, Global Evidence-Based Guidelines for the Management of Pancreatic Cystic Neoplasms Group

  • June 26, 2026

Related Content

Red cell distribution width: a novel and accessible predictor for immune checkpoint inhibitor-associated myocarditis—a retrospective cohort study

ESMO Breast Cancer 2026 Highlights Panel Discussion

Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Erica L. Mayer, MD, MPH; Nancy Lin, MD; and Ana C. Garrido-Castro, MD discuss important breast cancer research presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min
Crosstalk of factors underlying bone marrow niche-mediated chemoprotection in acute myeloid leukemia